PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34681618-8 2021 Afatinib diminished AKT phosphorylation at 30 min and 6 h in the EGFR- and EGFRvIII-overexpressing cells, respectively, and decreased AR phosphorylation in EGFR-overexpressing cells at 4 h. Afatinib or MK2206 combination therapy with the AR antagonist enzalutamide in the EGFR and EGFRvIII-overexpressing cells had synergistic efficacy. enzalutamide 252-264 AKT serine/threonine kinase 1 Homo sapiens 20-23 34439125-6 2021 Mechanistically, ELOVL5-mediated PUFA elongation enhanced the lipid raft-associated AKT-mTOR signaling activation and therefore contributes to the enzalutamide resistance. enzalutamide 147-159 AKT serine/threonine kinase 1 Homo sapiens 84-87 32205016-15 2020 CONCLUSIONS: The combination of capivasertib and enzalutamide is tolerable and has antitumour activity, with all responding patients harbouring aberrations in the PI3K/AKT/mTOR pathway. enzalutamide 49-61 AKT serine/threonine kinase 1 Homo sapiens 168-171 35533600-0 2022 Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. enzalutamide 77-89 AKT serine/threonine kinase 1 Homo sapiens 102-105 35533600-8 2022 These results suggest that the enhanced antitumor effects of enzalutamide by lycopene may be related to the reduction of AR protein levels through lycopene-mediated inhibition of AKT/EZH2 pathway, which may provide a new approach to improve the efficacy of enzalutamide in CRPC. enzalutamide 61-73 AKT serine/threonine kinase 1 Homo sapiens 179-182 32371590-0 2020 Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. enzalutamide 41-53 AKT serine/threonine kinase 1 Homo sapiens 19-22 32042320-13 2020 Conclusion: Our results for PDX models of LAR TNBC resistant to enzalutamide indicate that PIK3CA and AKT1 are potential therapeutic targets. enzalutamide 64-76 AKT serine/threonine kinase 1 Homo sapiens 102-106 31967357-0 2020 Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. enzalutamide 57-69 AKT serine/threonine kinase 1 Homo sapiens 83-86 31967357-3 2020 We previously found that a GLP-1 analog, exendin-4 (Ex-4), inhibited the growth of prostate cancer cells through suppressing the PI3K/Akt/mTOR pathway, which is activated in response to enzalutamide treatment and reported to be closely related to resistance to enzalutamide. enzalutamide 186-198 AKT serine/threonine kinase 1 Homo sapiens 134-137 31967357-4 2020 So we speculated that exendin-4 may enhance the sensitivity of prostate cancer to enzalutamide through inhibiting Akt activation. enzalutamide 82-94 AKT serine/threonine kinase 1 Homo sapiens 114-117 31967357-7 2020 Furthermore, the combination treatment significantly reduced Akt and mTOR levels that were triggered by enzalutamide administration, caused a further decrease in nuclear AR localization compared with the enzalutamide as a monotherapy (P < .5), though exendin-4 treatment alone showed no effect on nuclear AR. enzalutamide 104-116 AKT serine/threonine kinase 1 Homo sapiens 61-64 32054790-5 2020 XENT or XENT+ENZA inhibited IGF type 1 receptor (IGF-1R) and AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cells; XENT had no effect on AKT phosphorylation and proliferation in PTEN-null LNCaP or PC-3 cells. enzalutamide 13-17 AKT serine/threonine kinase 1 Homo sapiens 61-64 32054790-5 2020 XENT or XENT+ENZA inhibited IGF type 1 receptor (IGF-1R) and AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cells; XENT had no effect on AKT phosphorylation and proliferation in PTEN-null LNCaP or PC-3 cells. enzalutamide 13-17 AKT serine/threonine kinase 1 Homo sapiens 90-93 32054790-5 2020 XENT or XENT+ENZA inhibited IGF type 1 receptor (IGF-1R) and AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cells; XENT had no effect on AKT phosphorylation and proliferation in PTEN-null LNCaP or PC-3 cells. enzalutamide 13-17 AKT serine/threonine kinase 1 Homo sapiens 90-93 31228231-0 2019 Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. enzalutamide 115-127 AKT serine/threonine kinase 1 Homo sapiens 45-48 31228231-11 2019 Importantly, we demonstrate that PI3K/Akt signaling is activated in response to enzalutamide and mediates apoptosis evasion through inactivation of BAD, a BH3-only protein that activates proapoptotic signlaing through inhbition of BCL-xL. enzalutamide 80-92 AKT serine/threonine kinase 1 Homo sapiens 38-41 31228231-12 2019 Inhibition of Akt activates BAD, resulting in increased apoptosis and sensitivity to enzalutamide, demonstrating an alternative therapeutic strategy to target drug resistance. enzalutamide 85-97 AKT serine/threonine kinase 1 Homo sapiens 14-17 31126320-7 2019 Additionally, the combination of enzalutamide with USP14 inhibition/knockdown induced significant downregulation of AR proteins and suppression of AR-related signaling pathways, including Wnt/beta-catenin and PI3K/AKT pathways. enzalutamide 33-45 AKT serine/threonine kinase 1 Homo sapiens 214-217 31126320-8 2019 Moreover, AKT inhibition via MK2206 increased the antiproliferative and proapoptotic effects of enzalutamide+IU1 combined treatment. enzalutamide 96-108 AKT serine/threonine kinase 1 Homo sapiens 10-13 29220539-10 2018 However, enzalutamide alone has limited therapeutic utility attributed to feedback activation of the AKT-mTOR pathway. enzalutamide 9-21 AKT serine/threonine kinase 1 Homo sapiens 101-104 26378044-4 2015 We apply multiple prostate cancer cell models to demonstrate that enzalutamide induces differential activation of protein phosphatase-1 (PP-1) and Akt kinase depending on the gene context of cancer cells. enzalutamide 66-78 AKT serine/threonine kinase 1 Homo sapiens 147-150 25151012-11 2015 PATIENT SUMMARY: Targeting of the Akt and androgen receptor pathways with AZD5363 and enzalutamide, respectively, significantly delayed the development of enzalutamide-resistant prostate cancer through increased apoptosis and cell cycle arrest. enzalutamide 86-98 AKT serine/threonine kinase 1 Homo sapiens 34-37 25151012-11 2015 PATIENT SUMMARY: Targeting of the Akt and androgen receptor pathways with AZD5363 and enzalutamide, respectively, significantly delayed the development of enzalutamide-resistant prostate cancer through increased apoptosis and cell cycle arrest. enzalutamide 155-167 AKT serine/threonine kinase 1 Homo sapiens 34-37 27046225-0 2016 Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. enzalutamide 64-76 AKT serine/threonine kinase 1 Homo sapiens 9-12